Fibrosis is the formation of excess connective tissue in an organ. This process interferes with the normal tissue architecture and organ functioning, leading to a pathological state.

Axis Bio offer several preclinical models of fibrosis and can validate client-specific request if required.

• CCl4 model: The is a model used for the induction of liver fibrosis (after 2-4 weeks of treatment) or severe fibrosis (approaching cirrhosis) after 6-8 weeks. This model typically works on a therapeutic dosing schedule with dosing starting 2 weeks after induction of fibrosis. Animals are clinically assessed, and a Disease Index score calculated. Disease is confirmed by histology and blood samples can be taken for PD analysis.
• Cisplatin-Induced renal model: Nephrotoxicity of cisplatin is a major clinical problem. In treatment of lung cancer high dose cisplatin is still widely used and results in significant kidney damage. IP dosing of mice and rats with cisplatin results in kidney failure and this is a good preclinical model to test the efficacy of nephroprotective agents.
• Bleomycin-induced lung fibrosis model: Idiopathic pulmonary fibrosis is a chronic, progressive disease with no effective therapy. Axis Bio has validated a robust bleomycin-induced model to investigate novel therapeutic agents for this disease. Please see – link to full description page in our website (Respiratory section) – for more details.